Recent events
Recent events tied to this brand in public sources.
Back to profile61 entries · Page 3 of 4
2021
FDA approves Lyumjev for insulin-pump use
The US Food and Drug Administration expanded the label for Eli Lilly's Lyumjev, approving the 100 units/mL formulation for delivery through an insulin pump.
2021
Eli Lilly and MiNA Therapeutics enter research collaboration
Eli Lilly and MiNA Therapeutics entered a global research collaboration to develop therapies using MiNA’s small activating RNA technology platform. MiNA will apply the platform to up to five targets selected by Lilly.
2021
Former lobbyist sues Eli Lilly over alleged workplace discrimination and harassment
Former Eli Lilly lobbyist Sonya Elling filed a lawsuit alleging that company executives discriminated against and harassed women and retaliated against her. Eli Lilly was the only named defendant; a Lilly spokeswoman denied the allegations.
2021
Eli Lilly and Biolojic enter diabetes antibody therapy collaboration
Eli Lilly and Biolojic entered into an agreement under which Eli Lilly can use Biolojic's AI-based multi-antibody platform to discover and develop antibody-based diabetes treatments. The reported deal value was $121 million.
2021
Eli Lilly appoints Anat Ashkenazi CFO
Eli Lilly said Anat Ashkenazi will step into the role of senior vice president and chief financial officer.
2021
Eli Lilly CFO Josh Smiley resigns
Eli Lilly announced that CFO Josh Smiley resigned with immediate effect following a company probe that found inappropriate personal communications with multiple employees. The company said the conduct was not related to financial controls or business matters.
2021
Eli Lilly partners to establish Indiana COVID-19 infusion centers
Eli Lilly partnered with the state of Indiana and health systems to establish three infusion centers providing its COVID-19 antibody therapy.
2020
Eli Lilly announced an agreement to acquire Prevail Therapeutics
Eli Lilly announced it would acquire Prevail Therapeutics for about $1 billion. Under the agreement, Prevail shareholders would receive $22.50 per share, including a contingent value right tied to regulatory approval of a product in development.
2020
FDA authorizes Eli Lilly coronavirus antibody therapy for emergency use
The FDA granted emergency use authorization to a coronavirus antibody therapy made by Eli Lilly for people with mild to moderate symptoms who are at risk of more serious illness.
2020
Boryung acquires Korean rights to Gemzar
Boryung Pharmaceutical acquired all rights to Eli Lilly’s anti-cancer drug Gemzar in South Korea.
2020
Eli Lilly China partners with 1药网 on diabetes care
Eli Lilly China partnered with 1药网's online diabetes platform, providing a supply channel for its diabetes medicines and patient-management and benefit programmes for eligible patients.
2020
Lilly partners with Indiana health department on coronavirus testing
Eli Lilly partnered with the Indiana State Department of Health to accelerate coronavirus testing. Lilly’s scientists would facilitate SARS-CoV-2 testing at the company’s research laboratories, using samples from Indiana healthcare facilities.
2020
Lilly launches Reyvow migraine medicine
Eli Lilly launched Reyvow, an acute migraine medicine, after completion of a Drug Enforcement Administration review.
2020
Lilly sets Reyvow price at $640 per eight-pill pack
Lilly priced Reyvow at $640 per eight-pill pack. The article notes that patients' actual out-of-pocket costs may vary.
2020
Eli Lilly announces discounted insulin pens
Eli Lilly announced plans to offer discounted versions of two insulin pens for 50 percent less than their current list price; the pens were expected to be available by mid-April.
2020
Eli Lilly announces plan to acquire Dermira
Eli Lilly announced that it would acquire Dermira for $1.1 billion. The article reports the announcement as having come on Friday.
2019
Drugmakers agree to reduce prices of some medicines in China
Chinese regulators said pharmaceutical companies, including Roche and Novartis, agreed to reduce the China prices of some newer medicines by an average of 61% to enter the national medical insurance reimbursement list.
2019
Harris County files insulin price-fixing lawsuit
Harris County sued insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with pharmaceutical benefit managers Aetna Rx, CVS Caremark, Express Scripts and OptumRx, alleging they colluded to drive up insulin prices. The county seeks to recover more than $27 million it says it has paid to the companies.
2019
Eli Lilly reports third-quarter 2019 results
Eli Lilly announced its third-quarter 2019 financial results, reporting revenue of $5.477 billion and reported earnings per share of $1.37.
2019
Eli Lilly raises 2019 EPS guidance
Eli Lilly announced that it had raised its 2019 EPS guidance to $8.59–$8.69 on a reported basis and $5.75–$5.85 on a non-GAAP basis.